Frequently Asked Questions
The global automated and rapid microbiological tests market was valued at USD 6.2 Billion in 2022.
The automated and rapid microbiological tests market is expected to grow at a CAGR of 6.3% between 2023 and 2030, reaching USD 9.5 Billion in 2030.
Automated identification & susceptibility systems is the leading segment by class, holding over 38% share in terms of value in 2022.
The clinical segment governs the global demand for automated and rapid microbiological tests, holding a massive share of over 54% in 2022.
The automated blood culture systems segment will post the highest CAGR in the projected period.
Asia Pacific is fueling the rapid growth of the automated and rapid microbiological tests industry, with an over one-third share in 2022.
Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Abbott Laboratories, and Roche are the top market players. Other major players include BioMerieux SA, Oxoid Limited, MedMira, and Remel.
The major market drivers of the automated and rapid microbiological tests industry include increasing demand for point-of-care testing (POCT) solutions and advancements in diagnostic technologies.
The major market restraints of the automated and rapid microbiological tests industry include regulatory complexities, compliance challenges, and high initial investment costs associated with implementing automated testing systems.
The major market opportunities of the automated and rapid microbiological tests industry include a growing focus on antimicrobial stewardship programs and expanding applications in non-medical sectors such as food & beverage, pharmaceuticals, and environmental monitoring.